These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 23046127)

  • 1. Conformational variation in structures of classical and non-classical MHCII proteins and functional implications.
    Painter CA; Stern LJ
    Immunol Rev; 2012 Nov; 250(1):144-57. PubMed ID: 23046127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides.
    Pashine A; Busch R; Belmares MP; Munning JN; Doebele RC; Buckingham M; Nolan GP; Mellins ED
    Immunity; 2003 Aug; 19(2):183-92. PubMed ID: 12932352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility to HLA-DM protein is determined by a dynamic conformation of major histocompatibility complex class II molecule bound with peptide.
    Yin L; Trenh P; Guce A; Wieczorek M; Lange S; Sticht J; Jiang W; Bylsma M; Mellins ED; Freund C; Stern LJ
    J Biol Chem; 2014 Aug; 289(34):23449-64. PubMed ID: 25002586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism.
    Guce AI; Mortimer SE; Yoon T; Painter CA; Jiang W; Mellins ED; Stern LJ
    Nat Struct Mol Biol; 2013 Jan; 20(1):90-8. PubMed ID: 23222639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation.
    Mosyak L; Zaller DM; Wiley DC
    Immunity; 1998 Sep; 9(3):377-83. PubMed ID: 9768757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mechanism of HLA-DM induced peptide exchange in the MHC class II antigen presentation pathway.
    Schulze MS; Wucherpfennig KW
    Curr Opin Immunol; 2012 Feb; 24(1):105-11. PubMed ID: 22138314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural factors contributing to DM susceptibility of MHC class II/peptide complexes.
    Belmares MP; Busch R; Wucherpfennig KW; McConnell HM; Mellins ED
    J Immunol; 2002 Nov; 169(9):5109-17. PubMed ID: 12391227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-DM targets the hydrogen bond between the histidine at position beta81 and peptide to dissociate HLA-DR-peptide complexes.
    Narayan K; Chou CL; Kim A; Hartman IZ; Dalai S; Khoruzhenko S; Sadegh-Nasseri S
    Nat Immunol; 2007 Jan; 8(1):92-100. PubMed ID: 17143275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of peptide repertoire selection by HLA-DM.
    Pos W; Sethi DK; Wucherpfennig KW
    Trends Immunol; 2013 Oct; 34(10):495-501. PubMed ID: 23835076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC class II complexes sample intermediate states along the peptide exchange pathway.
    Wieczorek M; Sticht J; Stolzenberg S; Günther S; Wehmeyer C; El Habre Z; Álvaro-Benito M; Noé F; Freund C
    Nat Commun; 2016 Nov; 7():13224. PubMed ID: 27827392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-DM Stabilizes the Empty MHCII Binding Groove: A Model Using Customized Natural Move Monte Carlo.
    Demharter S; Knapp B; Deane C; Minary P
    J Chem Inf Model; 2019 Jun; 59(6):2894-2899. PubMed ID: 31070900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structures of an MHC class II molecule with covalently bound single peptides.
    Fremont DH; Hendrickson WA; Marrack P; Kappler J
    Science; 1996 May; 272(5264):1001-4. PubMed ID: 8638119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of carbohydrate antigen binding to the presentation protein HLA-DR.
    Cobb BA; Kasper DL
    Glycobiology; 2008 Sep; 18(9):707-18. PubMed ID: 18525076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-DM catalytically enhances peptide dissociation by sensing peptide-MHC class II interactions throughout the peptide-binding cleft.
    Reyes-Vargas E; Barker AP; Zhou Z; He X; Jensen PE
    J Biol Chem; 2020 Mar; 295(10):2959-2973. PubMed ID: 31969393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editing of the HLA-DR-peptide repertoire by HLA-DM.
    Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
    EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual hydrogen bonds play a critical role in MHC class II: peptide interactions: implications for the dynamic aspects of class II trafficking and DM-mediated peptide exchange.
    Sant AJ; Beeson C; McFarland B; Cao J; Ceman S; Bryant PW; Wu S
    Immunol Rev; 1999 Dec; 172():239-53. PubMed ID: 10631950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-DM recognizes the flexible conformation of major histocompatibility complex class II.
    Chou CL; Sadegh-Nasseri S
    J Exp Med; 2000 Dec; 192(12):1697-706. PubMed ID: 11120767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides.
    Pezeshki AM; Azar GA; Mourad W; Routy JP; Boulassel MR; Denzin LK; Thibodeau J
    Hum Immunol; 2013 Oct; 74(10):1280-7. PubMed ID: 23756162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of the non-classical MHC proteins HLA-DM and HLA-DO on loading of MHC class II molecules.
    Kropshofer H; Hämmerling GJ; Vogt AB
    Immunol Rev; 1999 Dec; 172():267-78. PubMed ID: 10631952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-DM and HLA-DO, key regulators of MHC-II processing and presentation.
    Mellins ED; Stern LJ
    Curr Opin Immunol; 2014 Feb; 26():115-22. PubMed ID: 24463216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.